Are you Céline Kernaleguen?

Claim your profile

Publications (3)9.28 Total impact

  • Energy Economics - ENERG ECON. 01/2011; 59.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to describe the evolution of hormone therapy (HT) initiation among newly postmenopausal women after the release of the first results from the Women's Health Initiative trial (July 2002). We used data from two French prospective cohorts, E3N and GAZEL. We identified 3,364 women with natural menopause onset occurring before 2002 and 1,880 women with menopause onset occurring after 2002. After 2002, the age-standardized rate of HT initiation (no later than 1 y after menopause onset) in newly postmenopausal women fell by 69.9% (67.9% and 74.8% in the E3N and GAZEL cohorts, respectively). There were also changes in the distribution of both the route of administration of estrogen and the type of associated progestogen, which made transdermal estrogen plus progesterone the predominant HT type initiated after 2002 (43.6% of the initiated HT, 44.0% and 42.2% in the Étude Épidémiologique auprès de femmes de l'Éducation Nationale and GAZEL cohorts, respectively). The evolution of HT initiation was similar in these two French cohorts, with a substantial drop in HT initiation rate accompanied by changes in the types of HT used.
    Menopause (New York, N.Y.) 10/2010; 18(2):219-23. · 3.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The increasing incidence rate of thyroid cancer warrants investigation of potentially modifiable factors, especially overweightness. Few prospective studies have investigated anthropometry from childhood to adulthood in relation to thyroid cancer. We analyzed data from 91,909 women of the E3N study, a cohort of French women insured by a national health scheme mostly covering teachers with the age of 40-65 years at inclusion in 1990. Risk estimates of first primary differentiated thyroid cancer (n = 317) were computed using Cox proportional hazards models. There was a significant dose-effect relationship between thyroid cancer risk and weight or body mass index (BMI) but not height. Compared with women whose BMI was 18.5-22 kg/m(2), women with BMI 22-25 and those with BMI over 30 had a 39% [95% confidence interval (CI) 7-81] and 76% (12-176) higher risk of thyroid cancer, respectively, with a 21% (5-39) increased risk per 5 kg/m(2) increase in BMI. A large body shape from age 35-40 was significantly associated with an increased risk of differentiated thyroid cancer when compared with a lean one, while earlier body shapes were not. The highest risk was observed in women whose body shape increased from lean to large between menarche and adulthood, with a HR of 2.17 (95% CI 1.04-4.53) when compared with women who were lean at both periods. Our study adds to the existing evidence in relation to excess weight to the risk of thyroid cancer, particularly in women whose body shape increased from menarche to adult age.
    International Journal of Cancer 11/2009; 126(12):2984-90. · 6.20 Impact Factor